Viking Therapeutics, Inc. (VKTX)

NASDAQ: VKTX · Real-Time Price · USD

26.22

+0.41 (1.59%)

Sep 30, 2025, 3:40 PM EDT - Market open

Viking Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Selling, General & Admin	57.52	49.28	37.02	16.12	10.7	10.73	Upgrade
Research & Development	155.32	101.64	63.81	54.23	44.98	31.93	Upgrade
Operating Expenses	212.84	150.92	100.83	70.36	55.68	42.66	Upgrade
Operating Income	-212.84	-150.92	-100.83	-70.36	-55.68	-42.66	Upgrade
Interest Expense	-0.1	-0.09	-0.09	-0.06	-0.02	-0.11	Upgrade
Interest & Investment Income	41.27	40.94	15.02	1.59	0.7	3.23	Upgrade
Currency Exchange Gain (Loss)	-	-	-	-	0.01	-	Upgrade
EBT Excluding Unusual Items	-171.66	-110.08	-85.9	-68.83	-54.99	-39.54	Upgrade
Gain (Loss) on Sale of Investments	0.11	0.11	-	-0.04	-	0.04	Upgrade
Pretax Income	-171.55	-109.96	-85.9	-68.87	-54.99	-39.5	Upgrade
Net Income	-171.55	-109.96	-85.9	-68.87	-54.99	-39.5	Upgrade
Net Income to Common	-171.55	-109.96	-85.9	-68.87	-54.99	-39.5	Upgrade
Shares Outstanding (Basic)	112	109	94	77	77	73	Upgrade
Shares Outstanding (Diluted)	112	109	94	77	77	73	Upgrade
Shares Change (YoY)	7.91%	15.57%	22.79%	-0.47%	6.34%	0.89%	Upgrade
EPS (Basic)	-1.54	-1.01	-0.91	-0.90	-0.71	-0.54	Upgrade
EPS (Diluted)	-1.54	-1.01	-0.91	-0.90	-0.71	-0.54	Upgrade
EBIT	-212.84	-150.92	-100.83	-70.36	-55.68	-42.66	Upgrade

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q